Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceritinib DDI Study with Warfarin and Midazolam
NCT02422589Phase 1Completed
- Sponsor
- Novartis
- Start
- Oct 2015
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of ceritinib in non-small cell lung cancer (NSCLC) and anaplastic lymphoma kinase gene rearrangement positive cancer, sponsored by Novartis. Primary endpoints: Area Under the Concentration-time Curve from Time Zero to Infinity, Area Under the Curve and 2 more. Started Oct 2015; status: completed.
02
Drugs
ceritinib
03
Conditions
non-small cell lung cancer (NSCLC)anaplastic lymphoma kinase gene rearrangement positive cancer
Beyond the preview
Go deeper on NCT02422589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02422589.